Ionis Pharmaceuticals, Inc. - Common Stock (IONS)

Ionis cut its full-year TRYNGOLZA sales outlook by roughly half as third-quarter sales of the drug only achieved $9.3 million; IONS investors who lost money may have legal rights as an investigation gets underway

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new long-term data for DAWNZERA® (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), to be presented at the 2026 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Phoenix, Arizona. Multiple presentations will demonstrate the long-term efficacy and safety of DAWNZERA in the OASISplus open-label extension (OLE) and switch cohorts over two years.

NEW YORK CITY, NY / ACCESS Newswire / November 11, 2026 / Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) disclosed on November 9, 2026 that TRYNGOLZA's launch in severe hypertriglyceridemia (sHTG) is ramping "more gradually than expected." IONS shares fell sharply as third-quarter sales of the drug dropped roughly 71% from the prior-year quarter. If you bought IONS and are now looking at losses, you may have legal rights. Affected shareholders are encouraged to start a confidential loss review now or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:

Ionis's $1.9 billion cash pile buys time, but it is still to be seen whether patient switches to DAWNZERA can offset a slower TRYNGOLZA launch.

Launch ramp slows and cash flow breakeven shifts a year to 2029.

Ionis Pharmaceuticals (NASDAQ:IONS) lowered its 2026 sales forecast for TRYNGOLZA after a slower-than-expected launch in severe hypertriglyceridemia, while pushing its target for sustained positive cash flow back by a year. The biotechnology company now expects approximately $50 million in full-yea

PHILADELPHIA, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS) following the Company’s November 9, 2026 announcement substantially reducing its full-year 2026 sales forecast for TRYNGOLZA (olezarsen).

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the third quarter ended September 30, 2026.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Monday, November 9 at 9:00 a.m. Eastern Time to discuss its third quarter 2026 financial results and highlight progress on key programs.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Roche announced today late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimized standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P<0.0001), relative to placebo at 37 weeks, as measured by 24-hour urine protein-to-creatinine ratio (UPCR). Proteinuria is a key indicator of kidney damage and a reduction in UPCR is strongly associated with the preservation of long-term kidney function. Results presented at the American Society of Nephrology (ASN) Kidney Week 2026 also showed that, among patients with baseline hematuria (blood in urine), a greater proportion of patients achieved hematuria resolution at Week 37 with sefaxersen versus placebo.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the company was named the top employer to work for by Science in its annual Top Employers survey of the biotech and pharmaceutical industries. Rising from #2 last year to #1, Ionis was recognized for its industry-leading innovation, talented employees and strong values-based culture.

This beaten-down biotech has a better story than its stock chart suggests.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy in adult patients without cirrhosis, receiving NrtI therapy for at least 6 months, who have suppressed HBV deoxyribonucleic acid (DNA), and with hepatitis B virus (HBV) surface antigen (HBsAg) levels ≤3000 IU/ml, as determined by an FDA-authorized test. GSK licensed bepirovirsen from Ionis and collaborated with them on its development.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the indication extension for TRYNGOLZA® (olezarsen) as an adjunct to diet, in combination with other lipid-lowering therapies, for the treatment of adult patients with severe hypertriglyceridemia (sHTG, fasting triglyceride levels of ≥880 mg/dL [≥10 mmol/L]). If confirmed by the European Commission (EC), TRYNGOLZA would be the first and only RNA-targeted therapy authorized in the EU for adults with sHTG and triglyceride levels ≥880 mg/dL (≥10 mmol/L). The positive CHMP opinion comes ahead of the previously anticipated timeline, with a final EC decision expected in the fourth quarter of 2026.

The sell-offs for both of these beaten-down biotech stocks appear to be overdone.

Wall Street expects an even bigger rebound for this beaten-down biotech stock.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner Roche today announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction, compared to placebo at 37 weeks, as measured by 24-hour urine protein-to-creatinine ratio (UPCR). Proteinuria is a key indicator of kidney damage, and a reduction in UPCR is strongly associated with the preservation of long-term kidney function. Sefaxersen is a once-monthly subcutaneous injection designed to enable self-administration for people with IgAN. The safety and tolerability profile of sefaxersen was consistent with previously reported data, with no new safety signals identified.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Development & Commercialization, Inc., today announced positive topline results from the Phase 3 FUSION trial evaluating ulefnersen, an investigational RNA-targeted medicine, in people living with amyotrophic lateral sclerosis (ALS) caused by mutations in the fused in sarcoma (FUS) gene, also known as FUS-ALS. The study met its primary endpoint, with ulefnersen demonstrating a statistically significant improvement on the primary endpoint assessing functional impairment and survival using a joint rank analysis of time to death or permanent ventilation, time to rescue1 and change in ALS Functional Rating Scale Revised (ALSFRS-R) score from baseline to Day 505 compared to placebo (p=0.0005), providing evidence from the first-ever placebo-controlled clinical study targeting the underlying genetic cause of FUS-ALS. Ulefnersen, discovered and developed by Ionis, is the first treatment to target the underlying genetic cause of FUS-ALS and demonstrate the potential to modify disease progression.

Shares of Ionis are down more than 40% so far this year.

Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia outlined recent regulatory wins, commercial-launch progress and several pipeline updates at the Morgan Stanley Global Healthcare Conference, while acknowledging setbacks in late-stage cardiovascular studies. Monia said the company has secured two

Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.

Ionis Pharmaceuticals is promising in multiple ways -- but it's not dirt cheap or without risks.